Do analysts prefer UDG or UPR?

Uniphar has a consensus price target of GBX 427.50, suggesting a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher possible upside, analysts plainly believe Uniphar is more favorable than UDG Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UDG Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Uniphar 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, UDG or UPR?

Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio UDG Healthcare £1.25B 0.00 N/A £25.40 N/A Uniphar £3.07B 0.36 £51.04M £19.50 21.64

Which has higher earnings & valuation, CTEC or UPR?

ConvaTec Group has higher earnings, but lower revenue than Uniphar. Uniphar is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ConvaTec Group £2.44B 1.63 £188.35M £8.60 23.72 Uniphar £3.07B 0.36 £51.04M £19.50 21.64

Do analysts rate UPR or MDC?

Uniphar presently has a consensus price target of GBX 427.50, indicating a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher probable upside, research analysts plainly believe Uniphar is more favorable than Mediclinic International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Uniphar 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Mediclinic International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor UPR or HIK?

In the previous week, Uniphar and Uniphar both had 1 articles in the media. Uniphar's average media sentiment score of 0.20 beat Hikma Pharmaceuticals' score of 0.06 indicating that Uniphar is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Uniphar 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hikma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend UPR or ABC?

Uniphar presently has a consensus price target of GBX 427.50, suggesting a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than Abcam. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Uniphar 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, UPR or ABC?

Uniphar has higher revenue and earnings than Abcam. Abcam is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Uniphar £3.07B 0.36 £51.04M £19.50 21.64 Abcam £350.40M 0.00 N/A £0.06 N/A

Is UPR or ABC more profitable?

Uniphar has a net margin of 1.66% compared to Abcam's net margin of 0.00%. Uniphar's return on equity of 13.14% beat Abcam's return on equity. Company Net Margins Return on Equity Return on Assets Uniphar 1.66% 13.14% 3.76% Abcam N/A N/A N/A

Uniphar (UPR) Competitors

GBX 422 +4.00 (+0.96%)

As of 12:36 PM Eastern

Compare

UPR vs. UDG, CTEC, MDC, HIK, and ABC

Should you buy Uniphar stock or one of its competitors? MarketBeat compares Uniphar with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Uniphar include UDG Healthcare (UDG), ConvaTec Group (CTEC), Mediclinic International (MDC), Hikma Pharmaceuticals (HIK), and Abcam (ABC). These companies are all part of the "medical" sector.

How does Uniphar compare to UDG Healthcare?

UDG Healthcare (LON:UDG) and Uniphar (LON:UPR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Uniphar had 1 more articles in the media than UDG Healthcare. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for UDG Healthcare. Uniphar's average media sentiment score of 0.20 beat UDG Healthcare's score of 0.00 indicating that Uniphar is being referred to more favorably in the news media.

Company	Overall Sentiment
UDG Healthcare	Neutral
Uniphar	Neutral

Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UDG Healthcare	£1.25B	0.00	N/A	£25.40	N/A
Uniphar	£3.07B	0.36	£51.04M	£19.50	21.64

34.8% of Uniphar shares are owned by institutional investors. 7.9% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Uniphar has a consensus price target of GBX 427.50, suggesting a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher possible upside, analysts plainly believe Uniphar is more favorable than UDG Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UDG Healthcare	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Uniphar	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Uniphar has a net margin of 1.66% compared to UDG Healthcare's net margin of 0.00%. Uniphar's return on equity of 13.14% beat UDG Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UDG Healthcare	N/A	N/A	N/A
Uniphar	1.66%	13.14%	3.76%

UDG Healthcare pays an annual dividend of GBX 0.17 per share. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. UDG Healthcare pays out 0.7% of its earnings in the form of a dividend. Uniphar pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Uniphar beats UDG Healthcare on 12 of the 15 factors compared between the two stocks.

How does Uniphar compare to ConvaTec Group?

ConvaTec Group (LON:CTEC) and Uniphar (LON:UPR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Uniphar had 1 more articles in the media than ConvaTec Group. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for ConvaTec Group. ConvaTec Group's average media sentiment score of 0.32 beat Uniphar's score of 0.20 indicating that ConvaTec Group is being referred to more favorably in the media.

Company	Overall Sentiment
ConvaTec Group	Neutral
Uniphar	Neutral

ConvaTec Group currently has a consensus price target of GBX 306, indicating a potential upside of 50.00%. Uniphar has a consensus price target of GBX 427.50, indicating a potential upside of 1.30%. Given ConvaTec Group's stronger consensus rating and higher possible upside, research analysts plainly believe ConvaTec Group is more favorable than Uniphar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ConvaTec Group	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Uniphar	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

68.1% of ConvaTec Group shares are held by institutional investors. Comparatively, 34.8% of Uniphar shares are held by institutional investors. 1.0% of ConvaTec Group shares are held by insiders. Comparatively, 7.9% of Uniphar shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ConvaTec Group pays an annual dividend of GBX 6.77 per share and has a dividend yield of 3.3%. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. ConvaTec Group pays out 78.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Uniphar pays out 10.1% of its earnings in the form of a dividend.

ConvaTec Group has a beta of 0.756, meaning that its share price is 24% less volatile than the broader market. Comparatively, Uniphar has a beta of 1.126, meaning that its share price is 13% more volatile than the broader market.

ConvaTec Group has a net margin of 7.17% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat ConvaTec Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ConvaTec Group	7.17%	10.53%	5.01%
Uniphar	1.66%	13.14%	3.76%

ConvaTec Group has higher earnings, but lower revenue than Uniphar. Uniphar is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ConvaTec Group	£2.44B	1.63	£188.35M	£8.60	23.72
Uniphar	£3.07B	0.36	£51.04M	£19.50	21.64

Summary

ConvaTec Group beats Uniphar on 11 of the 18 factors compared between the two stocks.

How does Uniphar compare to Mediclinic International?

Uniphar (LON:UPR) and Mediclinic International (LON:MDC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Uniphar had 1 more articles in the media than Mediclinic International. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for Mediclinic International. Uniphar's average media sentiment score of 0.20 beat Mediclinic International's score of 0.00 indicating that Uniphar is being referred to more favorably in the media.

Company	Overall Sentiment
Uniphar	Neutral
Mediclinic International	Neutral

Mediclinic International has higher revenue and earnings than Uniphar. Mediclinic International is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uniphar	£3.07B	0.36	£51.04M	£19.50	21.64
Mediclinic International	£3.38B	0.00	£169M	£0.23	N/A

Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Mediclinic International pays an annual dividend of GBX 3 per share. Uniphar pays out 10.1% of its earnings in the form of a dividend. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Uniphar is clearly the better dividend stock, given its higher yield and lower payout ratio.

Uniphar has a beta of 1.126, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Mediclinic International has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

34.8% of Uniphar shares are owned by institutional investors. Comparatively, 39.2% of Mediclinic International shares are owned by institutional investors. 7.9% of Uniphar shares are owned by company insiders. Comparatively, 48.9% of Mediclinic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mediclinic International has a net margin of 4.99% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Mediclinic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uniphar	1.66%	13.14%	3.76%
Mediclinic International	4.99%	5.50%	2.30%

Uniphar presently has a consensus price target of GBX 427.50, indicating a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher probable upside, research analysts plainly believe Uniphar is more favorable than Mediclinic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uniphar	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mediclinic International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Uniphar beats Mediclinic International on 11 of the 17 factors compared between the two stocks.

How does Uniphar compare to Hikma Pharmaceuticals?

Uniphar (LON:UPR) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Uniphar's net margin of 1.66%. Hikma Pharmaceuticals' return on equity of 15.83% beat Uniphar's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uniphar	1.66%	13.14%	3.76%
Hikma Pharmaceuticals	12.00%	15.83%	9.40%

Hikma Pharmaceuticals has higher revenue and earnings than Uniphar. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uniphar	£3.07B	0.36	£51.04M	£19.50	21.64
Hikma Pharmaceuticals	£3.35B	0.94	£353.21M	£181.00	8.15

34.8% of Uniphar shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 7.9% of Uniphar shares are owned by company insiders. Comparatively, 21.5% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Uniphar and Uniphar both had 1 articles in the media. Uniphar's average media sentiment score of 0.20 beat Hikma Pharmaceuticals' score of 0.06 indicating that Uniphar is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Uniphar	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hikma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.7%. Uniphar pays out 10.1% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Uniphar presently has a consensus price target of GBX 427.50, indicating a potential upside of 1.30%. Hikma Pharmaceuticals has a consensus price target of GBX 2,128, indicating a potential upside of 44.19%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Uniphar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uniphar	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Uniphar has a beta of 1.126, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.653, suggesting that its share price is 35% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats Uniphar on 13 of the 17 factors compared between the two stocks.

How does Uniphar compare to Abcam?

Uniphar (LON:UPR) and Abcam (LON:ABC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Uniphar presently has a consensus price target of GBX 427.50, suggesting a potential upside of 1.30%. Given Uniphar's stronger consensus rating and higher possible upside, analysts clearly believe Uniphar is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uniphar	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Uniphar had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for Abcam. Uniphar's average media sentiment score of 0.20 beat Abcam's score of 0.00 indicating that Uniphar is being referred to more favorably in the media.

Company	Overall Sentiment
Uniphar	Neutral
Abcam	Neutral

Uniphar has higher revenue and earnings than Abcam. Abcam is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uniphar	£3.07B	0.36	£51.04M	£19.50	21.64
Abcam	£350.40M	0.00	N/A	£0.06	N/A

Uniphar has a net margin of 1.66% compared to Abcam's net margin of 0.00%. Uniphar's return on equity of 13.14% beat Abcam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uniphar	1.66%	13.14%	3.76%
Abcam	N/A	N/A	N/A

34.8% of Uniphar shares are owned by institutional investors. 7.9% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Uniphar beats Abcam on 12 of the 13 factors compared between the two stocks.

Get Uniphar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPR vs. The Competition

Export

Metric	Uniphar	Medical Distribution Industry	Medical Sector	LON Exchange
Market Cap	£1.10B	£1.10B	£6.48B	£2.80B
Dividend Yield	0.43%	1.26%	2.67%	6.18%
P/E Ratio	21.64	5.81	23.97	366.94
Price / Sales	0.36	35.63	536.00	86,476.21
Price / Cash	9.97	9.97	27.48	27.85
Price / Book	3.31	3.31	10.47	7.77
Net Income	£51.04M	£51.04M	£3.56B	£5.89B
7 Day Performance	2.23%	-0.94%	0.87%	0.76%
1 Month Performance	13.59%	-0.51%	1.82%	1.84%
1 Year Performance	29.27%	7.72%	25.66%	73.86%

Uniphar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPR Uniphar	0.9971 of 5 stars	GBX 422 +1.0%	GBX 427.50 +1.3%	+28.0%	£1.10B	£3.07B	21.64	3,000	News Coverage
UDG UDG Healthcare	N/A	N/A	N/A	N/A	£2.72B	£1.25B	42.48	9,000
CTEC ConvaTec Group	4.7242 of 5 stars	GBX 202.60 +1.3%	GBX 306 +51.0%	-29.5%	£3.96B	£2.44B	23.56	10,000
MDC Mediclinic International	N/A	N/A	N/A	N/A	£3.69B	£3.38B	2,178.26	1,640
HIK Hikma Pharmaceuticals	3.7749 of 5 stars	GBX 1,480 -0.1%	GBX 2,128 +43.8%	-30.5%	£3.15B	£3.35B	8.18	9,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:UPR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Uniphar (UPR) Competitors

UPR vs. UDG, CTEC, MDC, HIK, and ABC

How does Uniphar compare to UDG Healthcare?

Summary

How does Uniphar compare to ConvaTec Group?

Summary

How does Uniphar compare to Mediclinic International?

Summary

How does Uniphar compare to Hikma Pharmaceuticals?

Summary

How does Uniphar compare to Abcam?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPR vs. The Competition

Uniphar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Uniphar (UPR) Competitors

UPR vs. UDG, CTEC, MDC, HIK, and ABC

How does Uniphar compare to UDG Healthcare?

Does the media refer more to UDG or UPR?

Which has better earnings and valuation, UDG or UPR?

Do insiders & institutionals believe in UDG or UPR?

Do analysts prefer UDG or UPR?

Is UDG or UPR more profitable?

Is UDG or UPR a better dividend stock?

Summary

How does Uniphar compare to ConvaTec Group?

Does the media prefer CTEC or UPR?

Do analysts rate CTEC or UPR?

Do institutionals & insiders believe in CTEC or UPR?

Is CTEC or UPR a better dividend stock?

Which has more volatility and risk, CTEC or UPR?

Is CTEC or UPR more profitable?

Which has higher earnings & valuation, CTEC or UPR?

Summary

How does Uniphar compare to Mediclinic International?

Does the media favor UPR or MDC?

Which has stronger earnings & valuation, UPR or MDC?

Is UPR or MDC a better dividend stock?

Which has more risk and volatility, UPR or MDC?

Do institutionals & insiders have more ownership in UPR or MDC?

Is UPR or MDC more profitable?

Do analysts rate UPR or MDC?

Summary

How does Uniphar compare to Hikma Pharmaceuticals?

Is UPR or HIK more profitable?

Which has stronger earnings & valuation, UPR or HIK?

Do institutionals & insiders have more ownership in UPR or HIK?

Does the media favor UPR or HIK?

Is UPR or HIK a better dividend stock?

Do analysts rate UPR or HIK?

Which has more risk and volatility, UPR or HIK?

Summary

How does Uniphar compare to Abcam?

Do analysts recommend UPR or ABC?

Does the media refer more to UPR or ABC?

Which has preferable earnings and valuation, UPR or ABC?

Is UPR or ABC more profitable?

Do insiders and institutionals have more ownership in UPR or ABC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPR vs. The Competition

Uniphar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools